2022 Fiscal Year Final Research Report
Clinical application of prognostic markers for pancreatic cancer to predict postoperative prognosis at the preoperative stage
| Project/Area Number |
20K07699
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
谷内 恵介 高知大学, 教育研究部医療学系臨床医学部門, 准教授 (50626869)
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 膵癌 / 予後予測マーカー |
|---|
| Outline of Final Research Achievements |
Through our own basic research, we identified RUVBL1 and PRDX1 associated with the invasiveness and metastasis of pancreatic cancer cells. Currently, we are conducting a retrospective clinical study for prognostic analysis of RUVBL1 and PRDX1 by immunohistochemical staining using 25 pancreatic cancer tissue samples preoperatively obtained by the fine-needle aspiration biopsy. In this study, (1) we completed the prognostic analysis of the retrospective study in 2022, and (2) we completed mouse experiments using human pancreatic cancer cell lines with knockdown of RUVBL1 and PRDX1.
This clinical study showed that the group with high expression of both RUVBL1 and PRDX1 had a significantly worse prognosis than the low expression group. In a basic study using a mouse model, the prognosis of mice transplanted with human pancreatic cancer cell line PANC-1 cells, in which the expression of RUVBL1 and PRDX1 was suppressed, showed a longer prognosis than that of the control group.
|
| Free Research Field |
消化器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
全身状態、CA19-9、肝転移、腹膜播種などが膵癌の予後予測因子として報告されている。しかし、これらの論文報告では、臨床病期との比較が詳細に行われていない。膵癌患者の予後を手術前に高い精度で予測できる方法を定めることができれば、特にステージIIAまでの切除可能膵癌において術前治療の適応基準を決めることが臨床の現場の重要課題であり、本研究の成果が術前化学療法を必要とする患者を絞り込むことに貢献できる可能性がある。本研究は、臨床病期だけでは不十分な予後予測を補完することのできる世界初のバイオマーカー同定を目指しており、臨床のニーズに合致した研究を推進できると考えている。
|
